Pfizer (PFE) Stock
Major global pharmaceutical company developing vaccines and medicines. Here's the price, business snapshot, and what's worth knowing about Pfizer in October 2026.
Pfizer Inc (PFE) is a large-cap global pharmaceutical company known for developing, producing and commercialising medicines and vaccines across areas such as oncology, immunology, rare disease and infectious disease. The company’s scale, diversified portfolio and R&D pipeline are key considerations for investors: revenue is driven by established products, new approvals and licensing or royalty arrangements. Important risks include regulatory decisions, patent expiries, pricing pressure, competition and litigation — all of which can materially affect earnings. Pfizer has historically returned capital to shareholders via dividends and buybacks, but dividend levels and capital allocation depend on cash flow and strategic priorities. For those researching the stock, focus on upcoming clinical readouts, regulatory milestones, patent timelines, and quarterly financials. This is general educational information, not personal advice; pharmaceutical stocks can be volatile and past performance is not a reliable indicator of future results.
Why It’s Moving
Pfizer Gains FDA Approval for Expanded Prostate Cancer Treatment and Reports Strong Vaccine Data
- The FDA expanded approval of TALZENNA (talazoparib) combined with XTANDI (enzalutamide) for men with metastatic hormone-sensitive prostate cancer carrying HRR gene mutations, including non-BRCA variants.
- Detailed results from a Phase 2 study showed Pfizer's investigational 25-valent pediatric pneumococcal conjugate vaccine elicited robust immune responses against all 25 serotypes with safety comparable to PREVNAR 20.
- While the broader healthcare sector faced selling pressure due to disappointing distant spread data in Moderna's melanoma vaccine trial, Pfizer held steady and edged higher, benefiting from its specific positive clinical and regulatory updates.
Pfizer Gains FDA Approval for Expanded Prostate Cancer Treatment and Reports Strong Vaccine Data
- The FDA expanded approval of TALZENNA (talazoparib) combined with XTANDI (enzalutamide) for men with metastatic hormone-sensitive prostate cancer carrying HRR gene mutations, including non-BRCA variants.
- Detailed results from a Phase 2 study showed Pfizer's investigational 25-valent pediatric pneumococcal conjugate vaccine elicited robust immune responses against all 25 serotypes with safety comparable to PREVNAR 20.
- While the broader healthcare sector faced selling pressure due to disappointing distant spread data in Moderna's melanoma vaccine trial, Pfizer held steady and edged higher, benefiting from its specific positive clinical and regulatory updates.
Sixth Month Growth Performance
When is the next earnings date for Pfizer (PFE)?
Pfizer has a confirmed upcoming earnings report scheduled for November 3, 2026, at 10:00 AM ET before the market opens. This release will cover the company's financial performance for the third quarter of 2026. Investors should note that this date aligns with Pfizer's historical pattern of reporting approximately three months after its previous August announcement.
Stock Performance Snapshot
Analyst Rating
Analysts suggest keeping Pfizer's stock as it is expected to remain stable around current levels.
Financial Health
Pfizer is showing strong revenue and profit generation, indicating solid financial stability and performance.
Dividend
Pfizer's dividend yield of 5.78% makes it appealing for investors seeking regular income. If you invested $1000 you would be paid $57.80 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Pipeline and innovation
Clinical readouts and regulatory approvals can shift expectations quickly, so investors often watch the pipeline closely — though outcomes can be uncertain.
Key revenue drivers
Vaccines, blockbusters and royalty agreements drive sales, but patent cliffs and pricing pressures can affect future revenue.
Global market reach
Pfizer operates worldwide with diverse market exposure, which can smooth regional volatility but also creates regulatory and geopolitical risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
